Clinical Trials Logo

Clinical Trial Summary

Pseudoxanthoma elasticum (PXE) is a rare, autosomal recessive genetic disease characterized by progressive calcification and fragmentation of elastic fibers in connective tissues. PXE primarily affect the skin, retina and arterial walls. Given the age of onset and progression of the disease, the consequences of PXE affect a large number of patients of working age and are therefore likely to have an impact on their professional career and job retention. To our knowledge, there are no studies on the occupational impact of PXE.


Clinical Trial Description

This is an epidemiological, descriptive and analytical, cross-sectional, monocentric study, carried out by telephone questionnaire on the national cohort of the PXE Reference Center in the Dermatology Department of the Angers University Hospital. Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes. The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire. In the absence of a validated questionnaire to meet the objectives of the study, a questionnaire was created. This questionnaire was tested in order to verify its feasibility and clarity. Medical data (age at diagnosis, age at referral to the Reference Centre, organ damage and clinical manifestations present at the time of the survey, treatments, etc.) will be collected from the medical file and the answers to the questionnaire will be collected by telephone on paper. Data will be collected in a coded manner. A correspondence list will be kept, under the responsibility of the principal investigator. No follow-up of patients is planned by the study. The results of this study should make it possible to provide new data on the impact of PXE on the career path and job retention of patients, as well as the medical reasons linked to it. It should also make it possible to improve knowledge on the experience of the consequences of PXE for patients in the workplace, as well as the actors and tools for job retention mobilised in these situations. All of these elements should make it possible to improve the prevention of the professional deintegration of PXE patients, in particular by setting up systematic and early management of patient-workers presenting a declared PXE. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05246189
Study type Observational
Source University Hospital, Angers
Contact
Status Completed
Phase
Start date April 7, 2022
Completion date September 9, 2022

See also
  Status Clinical Trial Phase
Completed NCT02537054 - Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) Phase 2
Completed NCT05569252 - A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum Phase 2
Recruiting NCT05662085 - Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Completed NCT03070860 - What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum N/A
Completed NCT01446393 - Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) N/A
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT03758534 - Natural History of GACI With or Without ARHR2 or PXE
Recruiting NCT05734196 - The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency Phase 1
Not yet recruiting NCT06462547 - ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency Phase 2
Recruiting NCT01446380 - Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort N/A
Recruiting NCT03813550 - Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study) N/A
Not yet recruiting NCT03364504 - Biological Collection of Kidney Cells N/A
Active, not recruiting NCT02108392 - Characterization of Pseudoxanthoma Elasticum
Recruiting NCT01731080 - Arterial Wall Calcium Load in Pseudoxanthoma Elasticum N/A
Completed NCT00555113 - Evolution of Visual Impairment During Pseudoxanthoma Elasticum N/A
Completed NCT00341419 - Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Withdrawn NCT04441671 - Oral Pyrophosphate Absorption in PXE Disease Phase 2
Recruiting NCT04868578 - PPI Supplementation to Fight ECtopIc Calcification in PXE N/A
Completed NCT05025722 - Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Completed NCT01525875 - Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Phase 2